The study objectives of  protocol TRC-0301 are:

1. To evaluate the response rate of bevacizumab (Avastin) combined with 5-FU/LV for patients with locally advanced or metastatic colorectal cancers who have disease progression after irinotecan-and oxaliplatin based- regimens.
2. To evaluate the time to progression and overall survival for patients with locally advanced or metastatic colorectal cancer receiving bevacizumab (Avastin) combined with 5-FU/LV after previous therapies with irinotecan-and oxaliplatin-based regimens.
3. To further evaluate the safety of bevacizumab when administered with a “bolus” 5-FU/LV regimen and with a “continuous infusion” 5-FU/LV regimen in patients previously treated with oxaliplatin and irinotecan.

The study objectives of  protocol TRC-0201 are:

1. To evaluate the toxicities of Oxaliplatin, 5-Fluorouracil, and calcium leucovorin when administered using the FOLFOX4 regimen over 2 days, every 2 weeks.
2. To evaluate the antitumor efficacy of the FOLFOX4 regimen as defined by the rate of time-to-progression and survival.
3. To capture data on subsequent therapy administered to patients who have received the FOLFOX4 regimen on this protocol.

All patients placed on the TRC-0201 protocol will be treated using the FOLFOX4 regimen if they meet eligibility criteria.